Wanhuida Intellectual Property

A ruling on the inventiveness of a compound patent for a prostate cancer therapeutic could help create uniform jurisprudence regarding the examination of pharmaceutical patents, says Guan Yue of Wanhuida Intellectual Property

Rui Wang of Wanhuida Intellectual Property says inventors should focus on improving AI systems’ transparency and predictability to enhance their patentability and identifies a challenge resulting from the interdisciplinary techniques involved in examination

Wu Xiaohui of Wanhuida Intellectual Property explains the significance of a ruling by the Supreme People’s Court after the rejection of an invention patent application

Feng Zheng and Xiaoyang Yang of Wanhuida Intellectual Property provide an insight into current Chinese practice concerning trade secrets and non-compete clauses/agreements based on the legal framework and recent court decisions

Wu Xiaoping of Wanhuida Intellectual Property comments on how hindsight bias contributed to an 'obviously erroneous’ ruling by the China National Intellectual Property Administration and welcomes the revised Guidelines for Patent Examination

Jianhui Li of Wanhuida Intellectual Property reports on a ruling by the China National Intellectual Property Administration that could shed light on the patent examination standards concerning cutting-edge siRNA inventions